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Letters to the EditorTo the Editor:
A recent study by Tamimi et al. [1] reported quantiﬁcation of the
levels of two apoptotic markers in the circulation of patients
suffering from non-alcoholic steatohepatitis (NASH): ‘‘caspase 3
generated cytokeratin-18 fragments’’ and soluble Fas (sFas). The
combined use of these markers was reported to accurately pre-
dict the presence of NASH, ‘‘supporting the potential usefulness
of these markers in clinical practice for noninvasive diagnosis
of NASH’’.
The method to detect caspase-cleaved keratin 18 (M30 Apop-
tosense ELISA) in this and other publications was developed by
PEVIVA AB (Bromma, Sweden) in collaboration with my labora-
tory at the Karolinska Institute [2]. The M30 Apoptosense test
was originally developed as a serum biomarker assay to deter-
mine therapy response of patients with carcinoma tumors [3,4].
Bantel et al. found the assay to be useful for the detection of liver
injury such as that occurring during hepatitis C virus (HCV) infec-
tion using patient blood samples [5]. Following this initial discov-
ery by Bantel et al., other investigators have found that also other
processes associated with hepatocyte apoptosis are associated
with increased levels of circulating caspase-cleaved K18 frag-
ments, including NASH [6] and alcoholic steatohepatitis (ASH)
[7].
The M30 Apoptosense ELISA assay is based on a monoclonal
antibody M30. This antibody recognizes a neo-epitope on K18
formed at Asp396 after cleavage by caspases [8]. The M30 anti-
body is well characterized and shown to be a marker of early
apoptosis [8]. Schutte and colleagues [9] demonstrated that the
cleavage site at Asp396 is generated by the initiator caspase 9,
explaining the cleavage of K18 at Asp396 during early stages of
apoptosis. This sequence is also susceptible to cleavage by cas-
pase 3 and 7 [9].
K18 fragments detected by the M30 Apoptosense assay are
frequently referred to as ‘‘M30’’ (e.g. ‘‘M30 levels in serum’’) in
the literature, which is incorrect since M30 is an antibody and
not an antigen. In the study by Tamimi et al. [1], the analyte is
referred to as ‘‘caspase 3 generated cytokeratin-18 fragments’’.
Since also other caspases cleave K18 at Asp396, this is only par-
tially correct. The fragments can be referred to as ‘‘ccK18’’ (‘‘cas-
pase-cleaved K18’’). Alternatively, since there is a second
caspase-cleavage site in the K18 molecule at Asp237 [10], a more
precise terminology would be ‘‘K18Asp396’’.
The ﬁndings by Tamimi et al. and by other investigators in the
ﬁeld, that caspase-cleaved K18/K18Asp396 is a useful biomarker
for the diagnosis and management of NASH are of large potentialJournal of Hepatology 2importance. To avoid confusion in a growing scientiﬁc ﬁeld, the
terminology used to describe the biomarker should be as precise
as possible.
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